Proteros teams up with Johnson & Johnson Innovation on sub-class of epigenetic targets
The new collaboration agreement is focused on the discovery of novel lead compounds against several epigenetic targets for various cancer indications. Under the agreement, Janssen gains access to Proteros' proprietary Nucleosomal Epigenetic Assay Technology (NEATTM) and discovery platform aimed at technically complex targets to identify quality lead compounds. Janssen has the option to license the lead compounds for further development and commercialization or the parties may jointly further develop and partner.
Financial terms of the collaboration were not disclosed.
Dr. Torsten Neuefeind, CEO of Proteros commented: "We are pleased to be working with Janssen to address a set of novel and complex epigenetic targets to create oncology drugs. We believe that the structure of the collaboration will accelerate the discovery of novel therapies and maximize the value generation for both parties."
Other news from the department science
Get the life science industry in your inbox
From now on, don't miss a thing: Our newsletter for biotechnology, pharma and life sciences brings you up to date every Tuesday and Thursday. The latest industry news, product highlights and innovations - compact and easy to understand in your inbox. Researched by us so you don't have to.